{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:54Z","timestamp":1787019594133,"version":"build-2736575974"},"reference-count":112,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","award":["SCAF\/16\/02"],"award-info":[{"award-number":["SCAF\/16\/02"]}],"id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,11,18]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Cystic fibrosis (CF) is a life-shortening, multi-organ, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most prominent clinical manifestation in CF is the development of progressive lung disease characterised by an intense, chronic inflammatory airway response that culminates in respiratory failure and, ultimately, death. In recent years, a new class of therapeutics that have the potential to correct the underlying defect in CF, known as CFTR modulators, have revolutionised the field. Despite the exciting success of these drugs, their impact on airway inflammation, and its long-term consequences, remains undetermined. In addition, studies querying the absolute requirement for infection as a driver of CF inflammation have challenged the traditional consensus on CF pathogenesis, and also emphasise the need to prioritise complementary anti-inflammatory treatments in CF. Macrophages, often overlooked in CF research despite their integral role in other chronic inflammatory pathologies, have increasingly become recognised as key players in the initiation, perpetuation and resolution of CF lung inflammation, perhaps as a direct result of CFTR dysfunction. These findings suggest that macrophages may be an important target for novel anti-inflammatory interventional strategies to effectively treat CF lung function decline. This review will consider evidence for the efficacy of anti-inflammatory drugs in the treatment of CF, the potential role of macrophages, and the significance of targeting these pathways at a time when rectifying the basic defect in CF, through use of novel CFTR modulator therapies, is becoming increasingly viable.<\/jats:p>","DOI":"10.1183\/13993003.03502-2020","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T14:19:12Z","timestamp":1611152352000},"page":"2003502","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages"],"prefix":"10.1183","volume":"57","author":[{"given":"Jonathan L.","family":"Gillan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-199X","authenticated-orcid":false,"given":"Donald J.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-2703","authenticated-orcid":false,"given":"Robert D.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"2024102102115572000_57.6.2003502.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2024102102115572000_57.6.2003502.2","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2024102102115572000_57.6.2003502.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2634339100"},{"key":"2024102102115572000_57.6.2003502.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature11130"},{"key":"2024102102115572000_57.6.2003502.5","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.4.7697234"},{"key":"2024102102115572000_57.6.2003502.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.3.638"},{"key":"2024102102115572000_57.6.2003502.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.12.005"},{"key":"2024102102115572000_57.6.2003502.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200703-409OC"},{"key":"2024102102115572000_57.6.2003502.9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav3488"},{"key":"2024102102115572000_57.6.2003502.10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41374-018-0026-7","article-title":"Lack of cystic fibrosis transmembrane conductance regulator disrupts fetal airway development in pigs","volume":"98","author":"Meyerholz","year":"2018","journal-title":"Lab Invest"},{"key":"2024102102115572000_57.6.2003502.11","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024102102115572000_57.6.2003502.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200213870"},{"key":"2024102102115572000_57.6.2003502.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0910283"},{"key":"2024102102115572000_57.6.2003502.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00903-2016"},{"key":"2024102102115572000_57.6.2003502.15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151570"},{"key":"2024102102115572000_57.6.2003502.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.15.6565"},{"key":"2024102102115572000_57.6.2003502.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2014.07.010"},{"key":"2024102102115572000_57.6.2003502.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019970"},{"key":"2024102102115572000_57.6.2003502.19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcf.2017.03.007","article-title":"Monocyte derived macrophages from CF pigs exhibit increased inflammatory responses at birth","volume":"16","author":"Paemka","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.20","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0412188"},{"key":"2024102102115572000_57.6.2003502.21","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0170OC"},{"key":"2024102102115572000_57.6.2003502.22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","article-title":"Developmental and functional heterogeneity of monocytes","volume":"49","author":"Guilliams","year":"2018","journal-title":"Immunity"},{"key":"2024102102115572000_57.6.2003502.23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000446825","article-title":"Cystic fibrosis lung immunity: the role of the macrophage","volume":"8","author":"Bruscia","year":"2016","journal-title":"J Innate Immun"},{"key":"2024102102115572000_57.6.2003502.24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2016.10.011","article-title":"The impact of impaired macrophage functions in cystic fibrosis disease progression","volume":"16","author":"L\u00e9v\u00eaque","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.25","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00541-17"},{"key":"2024102102115572000_57.6.2003502.26","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198005000-00003"},{"key":"2024102102115572000_57.6.2003502.27","first-page":"403","article-title":"Selective inhibition of phagocytic activity of rabbit alveolar macrophages by cystic fibrosis serum","volume":"109","author":"Boxerbaum","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"2024102102115572000_57.6.2003502.28","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.6.8520783"},{"key":"2024102102115572000_57.6.2003502.29","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70"},{"key":"2024102102115572000_57.6.2003502.30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00120-2015"},{"key":"2024102102115572000_57.6.2003502.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22558-5"},{"key":"2024102102115572000_57.6.2003502.32","doi-asserted-by":"publisher","DOI":"10.4161\/auto.7.11.17660"},{"key":"2024102102115572000_57.6.2003502.33","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1456"},{"key":"2024102102115572000_57.6.2003502.34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcf.2019.09.003","article-title":"Human cystic fibrosis monocyte derived macrophages display no defect in acidification of phagolysosomes when measured by optical nanosensors","volume":"19","author":"Law","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.202004-0991OC","article-title":"Single cell transcriptional archetypes of airway inflammation in cystic fibrosis","volume":"202","author":"Schupp","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102102115572000_57.6.2003502.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100396"},{"key":"2024102102115572000_57.6.2003502.37","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.11.5.819-824.2004"},{"key":"2024102102115572000_57.6.2003502.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.06.066"},{"key":"2024102102115572000_57.6.2003502.39","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210134"},{"key":"2024102102115572000_57.6.2003502.40","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00030.2009"},{"key":"2024102102115572000_57.6.2003502.41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200213572"},{"key":"2024102102115572000_57.6.2003502.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2005.11.001"},{"key":"2024102102115572000_57.6.2003502.43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcf.2017.03.011","article-title":"CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis","volume":"16","author":"Tarique","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97943"},{"key":"2024102102115572000_57.6.2003502.45","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3389\/fphar.2020.01129","article-title":"The resolution approach to cystic fibrosis inflammation","volume":"11","author":"Recchiuti","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024102102115572000_57.6.2003502.46","doi-asserted-by":"publisher","DOI":"10.1038\/ni1056"},{"key":"2024102102115572000_57.6.2003502.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14055-y"},{"key":"2024102102115572000_57.6.2003502.48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/reg2.97","article-title":"The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung","volume":"5","author":"Florez-Sampedro","year":"2018","journal-title":"Regeneration"},{"key":"2024102102115572000_57.6.2003502.49","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0407OC"},{"key":"2024102102115572000_57.6.2003502.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128062"},{"key":"2024102102115572000_57.6.2003502.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92929-0"},{"key":"2024102102115572000_57.6.2003502.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70343-8"},{"key":"2024102102115572000_57.6.2003502.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003233421204"},{"key":"2024102102115572000_57.6.2003502.54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1160OE"},{"key":"2024102102115572000_57.6.2003502.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503303321303"},{"key":"2024102102115572000_57.6.2003502.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.04.009"},{"key":"2024102102115572000_57.6.2003502.57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1513\/AnnalsATS.201706-486OC","article-title":"Association of high-dose ibuprofen use, lung function decline, and long-term survival in children with cystic fibrosis","volume":"15","author":"Konstan","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102102115572000_57.6.2003502.58","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32831311e8"},{"key":"2024102102115572000_57.6.2003502.59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024102102115572000_57.6.2003502.60","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2024102102115572000_57.6.2003502.61","first-page":"106","article-title":"Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung","volume":"129","author":"Martin","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"2024102102115572000_57.6.2003502.62","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1128\/iai.57.7.2187-2195.1989","article-title":"Induction of inflammatory mediators (histamine and leukotrienes) from rat peritoneal mast cells and human granulocytes by Pseudomonas aeruginosa strains from burn patients","volume":"57","author":"Bergmann","year":"1989","journal-title":"Infect Immun"},{"key":"2024102102115572000_57.6.2003502.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.12.009"},{"key":"2024102102115572000_57.6.2003502.64","first-page":"458","article-title":"In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist","volume":"297","author":"Birke","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2024102102115572000_57.6.2003502.65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis \u2013 study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"2024102102115572000_57.6.2003502.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2024102102115572000_57.6.2003502.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.10.003"},{"key":"2024102102115572000_57.6.2003502.68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1749"},{"key":"2024102102115572000_57.6.2003502.69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.563"},{"key":"2024102102115572000_57.6.2003502.70","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200601-071OC"},{"key":"2024102102115572000_57.6.2003502.71","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0628"},{"key":"2024102102115572000_57.6.2003502.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.02.001"},{"key":"2024102102115572000_57.6.2003502.73","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0155OC"},{"key":"2024102102115572000_57.6.2003502.74","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7150\/ijbs.5.667","article-title":"Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-\u03b3 stimulated macrophages","volume":"5","author":"Yamauchi","year":"2009","journal-title":"Int J Biol Sci"},{"key":"2024102102115572000_57.6.2003502.75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/cns.13092","article-title":"Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity","volume":"25","author":"Zhang","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"2024102102115572000_57.6.2003502.76","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41419-018-1097-5","article-title":"Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K\/Akt signaling pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"2024102102115572000_57.6.2003502.77","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201307-1200OC"},{"key":"2024102102115572000_57.6.2003502.78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46095"},{"key":"2024102102115572000_57.6.2003502.79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096681"},{"key":"2024102102115572000_57.6.2003502.80","first-page":"PA2565","article-title":"Azithromycin and nontuberculous mycobacteria: is there an association?","volume":"101","author":"Baskaran","year":"2016","journal-title":"Respiratory Infections"},{"key":"2024102102115572000_57.6.2003502.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.02.006"},{"key":"2024102102115572000_57.6.2003502.82","doi-asserted-by":"crossref","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102102115572000_57.6.2003502.83","doi-asserted-by":"crossref","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"2024102102115572000_57.6.2003502.84","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"},{"key":"2024102102115572000_57.6.2003502.85","first-page":"S317","article-title":"A double-blind, placebo-controlled phase 2 study in adults with cystic fibrosis of anabasum, a selective cannabinoid receptor type 2 agonist","volume":"52","author":"Chmiel","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2024102102115572000_57.6.2003502.86","doi-asserted-by":"crossref","first-page":"e00394","DOI":"10.1002\/prp2.394","article-title":"Ajulemic acid: potential treatment for chronic inflammation","volume":"6","author":"Burstein","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"2024102102115572000_57.6.2003502.87","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0489-0"},{"key":"2024102102115572000_57.6.2003502.88","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(02)01604-0"},{"issue":"Suppl. 2","key":"2024102102115572000_57.6.2003502.89","first-page":"242","article-title":"Lenabasum reduces LPS-induced inflammation in airway macrophages from human cystic fibrosis lungs","volume":"53","author":"Lubamba","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"2024102102115572000_57.6.2003502.90","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcf.2020.03.015","article-title":"Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis","volume":"19","author":"Tarique","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.91","unstructured":"Corbus Pharmaceuticals. Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint. www.corbuspharma.com\/press-releases\/detail\/342\/corbus-pharmaceuticals-announces-phase-2b-study-of?platform=hootsuite Date last accessed: October 8, 2020."},{"key":"2024102102115572000_57.6.2003502.92","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1635"},{"key":"2024102102115572000_57.6.2003502.93","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ymthe.2016.11.018","article-title":"Partial restoration of CFTR function in cftr-null mice following targeted cell replacement therapy","volume":"25","author":"Duchesneau","year":"2017","journal-title":"Mol Ther"},{"key":"2024102102115572000_57.6.2003502.94","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4172\/2157-7633.1000400","article-title":"Mesenchymal stem cell soluble mediators and cystic fibrosis","volume":"07","author":"Sutton","year":"2017","journal-title":"J Stem Cell Res Ther"},{"key":"2024102102115572000_57.6.2003502.95","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3389\/fimmu.2020.00581","article-title":"Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis","volume":"11","author":"Isopi","year":"2020","journal-title":"Front Immunol"},{"key":"2024102102115572000_57.6.2003502.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2024102102115572000_57.6.2003502.97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2024102102115572000_57.6.2003502.98","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102102115572000_57.6.2003502.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2024102102115572000_57.6.2003502.100","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00082-2019"},{"key":"2024102102115572000_57.6.2003502.101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102102115572000_57.6.2003502.102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024102102115572000_57.6.2003502.103","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves New Breakthrough Therapy for Cystic Fibrosis. www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis Date last accessed: January 22, 2020."},{"key":"2024102102115572000_57.6.2003502.104","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0703OC"},{"key":"2024102102115572000_57.6.2003502.105","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu944"},{"key":"2024102102115572000_57.6.2003502.106","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024102102115572000_57.6.2003502.107","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024102102115572000_57.6.2003502.108","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1165\/rcmb.2015-0322LE","article-title":"Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis","volume":"54","author":"Hisert","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102102115572000_57.6.2003502.109","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2019.08.021","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102102115572000_57.6.2003502.110","first-page":"61","article-title":"Potential of anti-inflammatory treatment for cystic fibrosis lung disease","volume":"3","author":"Taylor-Cousar","year":"2010","journal-title":"J Inflamm Res"},{"key":"2024102102115572000_57.6.2003502.111","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024102102115572000_57.6.2003502.112","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.11.008"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.03502-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:42:55Z","timestamp":1740364975000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.03502-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":112,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,4]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1183\/13993003.03502-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.03502-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}